BioLife Solutions Inc (BLFS)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	4,997	7,823	10,451	15,681	17,561	20,937	23,572	23,692	23,793	24,207	6,188	6,313	6,353	6,122	5,019	916	655	—	—	—
Total stockholders’ equity	US$ in thousands	348,909	325,461	321,442	333,405	337,663	332,017	352,128	358,107	364,188	405,120	409,544	476,075	478,047	489,259	452,281	208,777	204,429	186,851	105,843	67,709
Debt-to-equity ratio		0.01	0.02	0.03	0.05	0.05	0.06	0.07	0.07	0.07	0.06	0.02	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $4,997K ÷ $348,909K
= 0.01

The debt-to-equity ratio of BioLife Solutions Inc has been relatively low and stable from March 2020 to June 2021, with a value of 0.00. This indicates that the company was primarily financed by equity during this period. However, starting from June 2021, the ratio began to increase gradually, reaching 0.07 by December 2022. This uptrend suggests that BioLife Solutions started to rely more on debt financing as compared to equity.

Between December 2022 and March 2024, the debt-to-equity ratio fluctuated within a range of 0.03 to 0.07, indicating a mix of debt and equity in the company's capital structure. The ratio then decreased to 0.01 by December 2024, signaling a reduction in the company's reliance on debt financing.

Overall, the trend in the debt-to-equity ratio of BioLife Solutions Inc shows a shift towards higher leverage in the mid-term, followed by a slight decrease in the later periods. It is essential for stakeholders to monitor this ratio to assess the company's financial risk and capital structure management.